What 13 Analyst Ratings Have To Say About Genmab
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 13 analysts have published their opinion on Genmab (NASDAQ:GMAB) stock. The average price target is $43.62, implying an upside from the current price of $31.97. The average price target has increased by 25.24% over the past month.
October 13, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have given a bullish outlook for Genmab with an average price target of $43.62, indicating a potential upside from the current price.
The average price target given by analysts indicates a potential upside for the stock. This is a bullish signal and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100